中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

66 records (took 0.088 seconds)

    Gene Expression Technique
    4.
    发明申请
    Gene Expression Technique 有权
    基因表达技术

    公开(公告)号：US20120231505A1

    公开(公告)日：2012-09-13

    申请号：US13474313

    申请日：2012-05-17

    Applicant: Christopher John Arthur Finnis ,  Darrell Sleep ,  Gillian Shuttleworth

    Inventor： Christopher John Arthur Finnis ,  Darrell Sleep ,  Gillian Shuttleworth

    IPC: C12P21/00 ,  C12P21/08 ,  C12N9/16 ,  C12N9/72 ,  C12N9/04 ,  C12N9/90 ,  C12N9/64

    CPC classification number: C12N15/81 ,  A61K38/00 ,  C07K14/395 ,  C07K14/79 ,  C07K2319/35 ,  C12N9/90 ,  C12N2510/02

    Abstract: The present invention provides a method for producing a desired protein (such as a desired heterologous protein) comprising: (a) providing a host cell comprising a first recombinant gene encoding a protein comprising the sequence of a first chaperone protein, a second recombinant gene encoding a protein comprising the sequence of a second chaperone protein and a third gene, such as a third recombinant gene, encoding a desired protein (such as a desired heterologous protein), wherein the first and second chaperones are different; and (b) culturing the host cell in a culture medium to obtain expression of the first, second and third genes.

    Abstract translation: 本发明提供了一种生产所需蛋白质（例如所需异源蛋白质）的方法，包括：（a）提供宿主细胞，其包含编码包含第一伴侣蛋白序列的蛋白质的第一重组基因，编码第二分子伴侣蛋白的第二重组基因 包含第二伴侣蛋白和第三基因的序列的蛋白质，例如编码所需蛋白质（例如所需异源蛋白质）的第三重组基因，其中第一和第二伴侣不同; 和（b）在培养基中培养宿主细胞以获得第一，第二和第三基因的表达。

    Gene Expression Technique
    6.
    发明申请
    Gene Expression Technique 审中-公开
    基因表达技术

    公开(公告)号：US20110020865A1

    公开(公告)日：2011-01-27

    申请号：US11993335

    申请日：2006-06-22

    Applicant: Thomas Payne ,  Darrell Sleep ,  Christopher John Arthur Finnis ,  Leslie Robert Evans

    Inventor： Thomas Payne ,  Darrell Sleep ,  Christopher John Arthur Finnis ,  Leslie Robert Evans

    IPC: C12P21/06 ,  C12N1/19 ,  C12N15/74

    CPC classification number: C12N15/81 ,  C07K14/395 ,  C12P21/00

    Abstract: The present invention provides a host cell suitable for enhanced production of a protein product of choice characterised in that the host cell is genetically modified to cause over-expression of two or more helper proteins selected from a DnaJ-like protein (such as JEM1), an Hsp70 family protein (such as LHS1) and SIL1 wherein at least one of the over-expressed two or more helper proteins is selected from JEM1, LHS1 and SIL1, and wherein the DnaJ-like protein is not SCJ1.

    Abstract translation: 本发明提供了适合于增强产生所选蛋白质产物的宿主细胞，其特征在于宿主细胞被遗传修饰以引起选自DnaJ样蛋白（例如JEM1）的两种或更多种辅助蛋白的过表达， Hsp70家族蛋白（例如LHS1）和SIL1，其中至少一种过表达的两种或更多种辅助蛋白选自JEM1，LHS1和SIL1，并且其中DnaJ样蛋白不是SCJ1。

    Agent
    8.
    发明申请
    Agent 审中-公开
    代理人

    公开(公告)号：US20070149767A1

    公开(公告)日：2007-06-28

    申请号：US10548915

    申请日：2004-03-15

    Applicant: Michael Grandgeorge ,  Darrell Sleep

    Inventor： Michael Grandgeorge ,  Darrell Sleep

    IPC: C07K14/765

    CPC classification number: C07K14/765 ,  A61K38/38 ,  C07K14/76 ,  C07K2319/00 ,  C12N15/62

    Abstract: An agent having a greater half-life than naturally produced albumin in a patient with NS, the agent comprising an albumin-like first polypeptide bound to a second polypeptide, wherein the second polypeptide, when bound to the albumin-like first polypeptide is therapeutically inert and wherein if the agent consists of two albumin molecules, then they are covalently joined to one another other than solely by means of one or more cysteine-cysteine disulphide bridges.

    Abstract translation: 在具有NS的患者中具有比天然产生的白蛋白更大的半衰期的药剂，所述药物包含与第二多肽结合的白蛋白样第一多肽，其中所述第二多肽当与白蛋白样第一多肽结合时是治疗惰性的 并且其中如果所述试剂由两个白蛋白分子组成，则它们除了仅通过一个或多个半胱氨酸 - 半胱氨酸二硫桥外，彼此共价连接。

    Albumin-fused anti-angiogenesis peptides
    9.
    发明申请
    Albumin-fused anti-angiogenesis peptides 审中-公开
    白蛋白融合的抗血管生成肽

    公开(公告)号：US20060122374A1

    公开(公告)日：2006-06-08

    申请号：US10503836

    申请日：2003-02-07

    Applicant: Peter Mertins ,  Iihan Celik ,  Oliver Elaker ,  Darrell Sleep ,  Joanna Hay ,  Hans-Peter Hanger

    Inventor： Peter Mertins ,  Iihan Celik ,  Oliver Elaker ,  Darrell Sleep ,  Joanna Hay ,  Hans-Peter Hanger

    IPC: C07K14/765 ,  A61K38/37

    CPC classification number: A61K38/39 ,  A01K2217/05 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K47/643 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/005 ,  C07K14/47 ,  C07K14/765 ,  C07K14/78 ,  C07K14/8114 ,  C07K2319/00 ,  C07K2319/31 ,  C12N15/62 ,  C12N2740/16122 ,  C12Y301/26003

    Abstract: The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acuds, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis.

    Abstract translation: 本发明涉及包含血管生成抑制肽（例如内皮抑素肽（包括但不限于其片段和变体））的蛋白质，其表现出与白蛋白融合或缀合的抗逆转录病毒活性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及抑制血管内皮细胞增殖和肿瘤发生生成诱导的细胞融合的组合物和方法。 本发明还涉及预防原发性肿瘤和转移瘤的生长或促进消退的组合物和方法; 并用于治疗癌症，糖尿病性视网膜病变，进行性黄斑变性或类风湿性关节炎。

    Modulation of cellular proliferation with thymidine phosphorylase
    10.
    发明授权
    Modulation of cellular proliferation with thymidine phosphorylase 失效
    用胸苷磷酸化酶调节细胞增殖

    公开(公告)号：US06290953B1

    公开(公告)日：2001-09-18

    申请号：US08584760

    申请日：1996-01-11

    Applicant: David J. Ballance ,  Michael G. Courtney ,  Christopher J. A. Finnis ,  Darrell Sleep

    Inventor： David J. Ballance ,  Michael G. Courtney ,  Christopher J. A. Finnis ,  Darrell Sleep

    IPC: H01J1982

    CPC classification number: C12N9/1077 ,  A61K38/00 ,  A61K47/6815

    Abstract: A method of modulating cellular proliferation by the application of a thymidine phosphorylase to an organism. In a further aspect of the subject method, the thymidine phosphorylase is a conjugate which includes a targeting portion adapted to target the conjugate to a specific cell type or anatomical location. The thymidine phosphorylase has a thymidine phosphorylase activity of at least about 5%, preferably at least about 50% and, most preferably, at least about 90%, of the native E. coli enzyme.

    Abstract translation: 通过将胸苷磷酸化酶应用于生物来调节细胞增殖的方法。 在本发明方法的另一方面，胸苷磷酸化酶是包含适于将缀合物靶向特定细胞类型或解剖位置的靶向部分的缀合物。 胸苷磷酸化酶具有至少约5％，优选至少约50％，最优选至少约90％的天然大肠杆菌酶的胸苷磷酸化酶活性。

Patent Agency Ranking